Embecta Completes Acquisition of Assets From BD

Embecta Corp. (EMBC) completed the acquisition of assets and liabilities from Becton Dickinson on May 15 2026 according to an 8-K filed with the SEC the same day.

The filing discloses completion of the transaction under Item 2.01. Embecta acquired a defined set of assets and assumed associated liabilities from BD in exchange for cash consideration. The deal closed on the filing date. Item 7.01 contains Regulation FD disclosure and Item 9.01 includes financial statements and exhibits required to document the transaction.

The acquisition transfers operational responsibility for the purchased business lines from BD to Embecta effective May 15 2026. Prior to closing the assets and related operations remained under BD control. Post-closing Embecta assumes day-to-day management integration of the acquired assets and any associated contracts or regulatory permits.

The filing does not disclose the exact dollar amount of consideration or the specific asset classes transferred beyond the generic description in Item 2.01.

Downstream the transaction starts the clock on any remaining post-closing contractual milestones between the parties. Embecta must incorporate the acquired financial results into its subsequent periodic SEC reports. If the acquired assets include product lines subject to FDA oversight or other regulatory approvals those compliance obligations now sit with Embecta.

Markets and counterparties will receive updated consolidated financial statements reflecting the new ownership structure in Embecta's next quarterly or annual filing.

This marks the final step in a divestiture process initiated by BD. The 8-K represents the official closing record required under SEC rules for material asset acquisitions by a public company. No further immediate regulatory approvals are referenced in the filing.